Board of Directors Update - Karen J Wilson appointed to the Board of Directors bringing over three decades of leadership experience in the life sciences sector [1][3] - Steven Mintz departed from the Board of Directors after contributing to the company's transition from private to public [4] POZ Platform Technology - Proprietary POZ technology based on poly(2-oxazoline) polymer enables greater control in drug loading and precision in drug release rate [5] - POZ technology aims to improve pharmacokinetic profiles of drugs with narrow therapeutic windows [5] - Potential applications across a broad range of payloads and indications with ongoing out-licensing and partnership arrangements including a non-exclusive license agreement with Pfizer [6] Company Overview - Clinical-stage biotechnology company developing wholly owned drug product candidates for neurological diseases and other indications [7] - POZ Platform technology has potential to improve efficacy and safety profiles of small molecules RNA-based therapeutics and antibody-based drug conjugates [7] - Headquarters located in Huntsville Alabama on the campus of the HudsonAlpha Institute of Biotechnology [7]
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors